From a biological rationale perspective, it is envisaged that PARP inhibitors are active irrespective of whether a BRCA1/2 variant is of germline or somatic origin as both result in the loss of function of both copies of BRCA1 or BRCA2 in the tumor (Dougherty et al., 2017). This evidence concerns the gene BRCA2 and neoplasm.